10 recruiting, 3 terminated, 2 active not recruiting, 2 not yet recruiting. 12 Phase 2, 3 Not applicable, 3 Phase 1, 2 Phase 3.
Follow PSMA PET Scan: new trials by email Literature Review of PSMA PET Scan trials Research Report on PSMA PET Scan
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Measuring Circulating Tumor Deoxyribonucleic Acid Tumor Fraction to Guide Early 177Lu-PSMA-617 Treatment Discontinuation in Patients With Metastatic Castration-Resistant Prostate Cancer, DYNAMO Trial Lutetium Lu 177 Vipivotide Tetraxetan, Cell-free Circulating Tumor DNA Assay, Computed Tomography - Metastatic Castration-Resistant Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8 | Phase 2 | Recruiting | University of Washington | 64 | 2026-11-15 | 2026-10-19 |
| Pluvicto for the Treatment of African American Men With Metastatic Castration-Resistant Prostate Cancer Biopsy Procedure, Biospecimen Collection, Bone Scan - Metastatic Castration-Resistant Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8 | Phase 2 | Not yet recruiting | Emory University | 88 | 2026-11-02 | 2026-10-06 |
| Testing the Safety of the Anti-cancer Drug, Sn-117m-DTPA, for Advanced Cancers That Have Spread to Bones Biospecimen Collection, Bone Scan, Computed Tomography - Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma | Phase 1 | Withdrawn | National Cancer Institute (NCI) | 2026-10-01 | 2026-08-28 | |
| Focal Radiation Therapy (HDR-Brachytherapy) for the Treatment of Prostate Cancer Biopsy Procedure, Biospecimen Collection, High-Dose Rate Brachytherapy - Prostate Adenocarcinoma, Stage I Prostate Cancer American Joint Committee on Cancer (AJCC) v8 | Not applicable | Recruiting | Jonsson Comprehensive Cancer Center | 45 | 2026-05-11 | 2026-05-22 |
| Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Advanced Prostate Cancer, RECIPROCAL Trial Lutetium Lu 177 Vipivotide Tetraxetan, Biospecimen Collection, Patient Monitoring - Metastatic Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma | Phase 3 | Recruiting | Alliance for Clinical Trials in Oncology | 1524 | 2026-03-31 | 2026-10-02 |
| 177^Lu-PSMA-617 in Combination With Sipuleucel-T for the Treatment of Metastatic Castration-Resistant Prostate Cancer Biospecimen Collection, Bone Scan, Computed Tomography - Metastatic Castration-Resistant Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8 | Phase 1 | Recruiting | City of Hope Medical Center | 30 | 2026-03-06 | 2026-04-20 |
| Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial Androgen Therapy, Apalutamide, Docetaxel - Castration-Sensitive Prostate Carcinoma, Metastatic Prostate Adenocarcinoma | Phase 3 | Recruiting | Alliance for Clinical Trials in Oncology | 1260 | 2025-12-01 | 2026-10-02 |
| Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial Genetic testing, Valemetostat Tosylate, Magnetic Resonance Imaging - Castration-Resistant Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8 | Phase 2 | Recruiting | Alliance for Clinical Trials in Oncology | 474 | 2025-02-06 | 2026-10-02 |
| Phase 2 Randomized Trial of Flexible Dosing Schedule of 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer (FLEX-MRT) Computed Tomography, Gallium Ga 68 Gozetotide, Lutetium Lu 177 Vipivotide Tetraxetan - Prostate Carcinoma, Stage IVB Prostate Cancer American Joint Committee on Cancer (AJCC) v8 | Phase 2 | Recruiting | Jonsson Comprehensive Cancer Center | 90 | 2024-08-01 | 2026-03-10 |
| Golimumab and Apalutamide for the Treatment of Castration-Resistant Prostate Cancer, TRAMP Study Apalutamide, Biopsy, Biospecimen Collection - Metastatic Castration-Resistant Prostate Carcinoma, Prostate Adenocarcinoma | Phase 2 | Terminated | University of Washington | 8 | 2024-05-23 | 2026-10-19 |
| Carboplatin Chemotherapy Before Surgery for People With High-Risk Prostate Cancer and an Inherited BRCA1 or BRCA2 Gene Mutation Biospecimen Collection, Carboplatin, Chest Radiography - Prostate Adenocarcinoma, Stage IIIB Prostate Cancer AJCC v8 | Phase 2 | Recruiting | SWOG Cancer Research Network | 44 | 2024-03-01 | 2026-01-29 |
| Relugolix in Combination With Radiation Therapy for Treating Patients With High Risk Prostate Cancer Biospecimen Collection, Bone Scan, Brachytherapy - Stage IIC Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8 | Phase 2 | Not yet recruiting | University of Kansas Medical Center | 90 | 2023-11-20 | 2023-11-13 |
| Vudalimab (XmAb20717) in Combination With Standard of Care Treatment in Patients With Metastatic Castration Sensitive Prostate Cancer Abiraterone, Biospecimen Collection, Bone Scan - Castration-Sensitive Prostate Carcinoma, Metastatic Prostate Adenocarcinoma | Phase 1 | Terminated | Emory University | 4 | 2023-08-03 | 2025-09-15 |
| PSMA PET Scan and mpMRI for Prostate Cancer Detection PSMA PET scan, No PSMA PET, 18F- DCFPyl Injection - Prostate Cancer Diagnosis | Phase 2 | Unknown | VA Greater Los Angeles Healthcare System | 100 | 2023-05-01 | 2023-04-24 |
| MRI Guided Radiation Therapy for the Treatment of High Risk Prostate Cancer MRI-guided Intensity-Modulated Radiation Therapy, Antiandrogen Therapy, PSMA PET Scan - Prostate Adenocarcinoma, Stage IIIB Prostate Cancer AJCC v8 | Phase 2 | Terminated | Thomas Jefferson University | 6 | 2022-11-16 | 2026-03-03 |
| Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer, The NRG Promethean Study Biospecimen Collection, Bone Scan, Computed Tomography - Oligometastatic Prostate Carcinoma, Prostate Adenocarcinoma | Phase 2 | Active not recruiting | NRG Oncology | 194 | 2022-04-20 | 2026-08-17 |
| MRI-guided Transurethral Urethral Ultrasound Ablation for the Treatment of Low to Intermediate Grade Prostate Cancer MRI-Guided Transurethral Ultrasound Ablation, Questionnaire Administration, Digital Rectal Examination - Prostate Carcinoma, Stage I Prostate Cancer AJCC v8 | Not applicable | Recruiting | Mayo Clinic | 100 | 2022-04-06 | 2026-07-22 |
| MC200708 Pemetrexed and Pembrolizumab for the Treatment of Recurrent and/or Metastatic Salivary Gland Cancer Pembrolizumab, Pemetrexed Disodium, Biospecimen Collection - Metastatic Salivary Gland Carcinoma, Recurrent Salivary Gland Carcinoma | Phase 2 | Active not recruiting | Mayo Clinic | 45 | 2021-07-23 | 2026-06-04 |
| Prostate Specific Membrane Antigen (PSMA) or (FACBC) PET/CT Site-Directed Therapy for Treatment of Prostate Cancer, Flu-BLAST-PC Study Positron Emission Tomography, Lymphadenectomy, Radiation Therapy - Prostate Adenocarcinoma | Phase 2 | Recruiting | University of Washington | 100 | 2020-09-30 | 2026-07-07 |
| Comparison of PET Imaging Patterns With PSMA and AR Expression in Prostate Cancer and Bladder Cancer PSMA PET Scan, FDHT PET Scan - Prostate Cancer | Not applicable | Completed | Medical University of Vienna | 10 | 2020-02-01 | 2023-03-17 |
Prostatic Neoplasms (17) · Breast Neoplasms (1) · Carcinoma, Adenoid Cystic (1) · Carcinoma, Non-Small-Cell Lung (1) · Lung Neoplasms (1) · Salivary Gland Neoplasms (1)
Alliance for Clinical Trials in Oncology (3) · University of Washington (3) · Emory University (2) · Jonsson Comprehensive Cancer Center (2) · Mayo Clinic (2) · City of Hope Medical Center (1) · Medical University of Vienna (1) · NRG Oncology (1) · National Cancer Institute (NCI) (1) · SWOG Cancer Research Network (1) · Thomas Jefferson University (1) · University of Kansas Medical Center (1) · VA Greater Los Angeles Healthcare System (1)
United States (18) · Austria (1) · Canada (1)
Alan C Lee (1) · Alex Chehrazi-Raffle, MD (1) · Ashish Chintakuntlawar, MBBS, PhD (1) · Bassel Nazha, MD, MPH (1) · Bridget F Koontz (1) · David A Woodrum, MD, PhD (1) · Evan Yu (1) · Heather H Cheng (1) · Jacob E Berchuck, MD (1) · Jeremie Calais (1) · Jessie DiNome, MD (1) · Katherine A. Price, MD (1) · Michael Schweizer, MD (1) · Rana McKay, MD (1) · Ruben Raychaudhuri, MD (1)
P30CA138292 (2), P30CA033572 (1), P30CA168524 (1), U10CA180868 (1), U10CA180888 (1), UM1CA186712 (1)